Long noncoding RNA LINC00261 was reported to be downregulated in multiple cancers. LINC00261 overexpression inhibits cancer cell proliferation, migration, and invasion. But the expression and function of LIN00261 in endometrial carcinoma are still elusive. We found that LINC00261 mRNA levels were downregulated in endometrial carcinoma, and LINC00261 overexpression inhibited endometrial carcinoma cell proliferation, migration, and invasion. miRNAs, including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1.
Long noncoding RNA LINC00261 was reported to be downregulated in multiple cancers. LINC00261 overexpression inhibits cancer cell proliferation, migration, and invasion. But the expression and function of LIN00261 in endometrial carcinoma are still elusive. We found that LINC00261 mRNA levels were downregulated in endometrial carcinoma, and LINC00261 overexpression inhibited endometrial carcinoma cell proliferation, migration, and invasion. miRNAs, including miR-182, miR-183, miR-153, miR-27a, and miR-96, were predicted to bind LINC00261 and FOXO1, and functioned to attenuate expression of LINC00261 and FOXO1.
Overexpressed LINC00261 lowered these dissociative miRNAs, resulting in increase of FOXO1 protein levels. The knockdown of FOXO1 eliminated the suppression effect of overexpressed LINC00261 on endometrial carcinoma cell aggressiveness.
LINC00261 promotes FOXO1 expression through reducing FOXO1-targeted miRNAs to suppress endometrial carcinoma cell proliferation, migration, and invasion.
Significance of the study LINC00261 is downregulated in endometrial carcinoma and associated with metastasis of this cancer. LINC00261 elevates FOXO1 protein levels through reducing FOXO1-targeted miRNAs to suppress endometrial carcinoma cell proliferation, migration, and invasion. women, but the number is increasing in younger women, 1 and around 25% of all women with endometrial cancer are premenopausal and 5% are diagnosed at younger than 40 years old. 2 Endometrial cancer is mainly classified into 2 types to determine the risk of metastasis and recurrence 3 : Type I tumours are oestrogen-dependent, often responsive to oestrogen and portend a good prognosis, and type II tumours are oestrogen-independent, rarely responsive to oestrogen and carry a poor outcomes. However, endometrial carcinoma treatment options are still limited, and the recurrence rates of type I and type II tumours are around 20% and 50% of cases, respectively. 4 It is an urgent need to deeply study the molecular mechanisms underlying endometrial carcinoma to identify new potential therapeutic targets. Forty-eight hours later, 500 μg/mL G418 (InvivoGen, USA) was added into the cell medium and maintained around 1 month to obtain the stable cell lines.
| Quantitative reverse transcription PCR
Endometrial cancer tissues and matched adjacent nontumour tissues were obtained from endometrial cancer patients with a signed informed consent. This study was approved by the Ethic Committee of the Second People's Hospital of Hefei. The tissues were put into 1 mL TRIzol (Thermo Fisher, USA) and homogenized, followed by total RNA purification according to the manufacturer's instruction. RNAs were reverse transcribed into cDNA with the PrimeScript RT Reagent Kit (Takara, Otsu, Japan). Real-time PCR was carried out using SYBR Green Real-Time PCR Master Mix (Takara, Japan) with Applied
Biosystems 7300 Real-Time PCR System.
| Cell proliferation assays
Cell number counting assay and MTT assay were used to measure the cell proliferation.
For cell number counting assay, 1 × 10 5 cells per well were seeded in 6-well plates, and the total cell number of each well was counted every 24 hours for 5 days.
For MTT assay, 1 × 10 4 cells per well were seeded in 96-well plates and grew to 80% confluence. Fifteen microlitre MTT solution (Sigma-Aldrich) was added into each well and incubated for 4 hours.
The medium was removed, and then, 200 μL of DMSO was added into each well to dissolve the formazan. The optical density was measured at 490 nm using microplate reader (Tecan).
| Transwell migration and invasion assays
To perform transwell migration assay, cells (5 × 10 4 cells per chamber)
in 500 μL FBS-free medium were seeded to the upper chamber of 3 | RESULTS
| LINC00261 is downregulated in endometrial carcinoma
To investigate the role of LINC00261 in endometrial carcinoma, we first examined the expression of this lncRNA in this cancer. Normal endometrium and endometrial carcinoma tissues were collected from 20 healthy people and 69 patients with endometrial carcinoma, respectively. The 69 cases of endometrial carcinoma included 33 cases with lymphatic metastasis and 36 without lymphatic metastasis.
LINC00261 mRNA levels were determined by qRT-PCR. GAPDH expression was used as an internal control. As shown in Figure 1A , LINC00261 was significantly decreased in endometrial carcinoma.
Moreover, lncRNA expression was further lower in endometrial carcinoma with lymphatic metastasis compared to those without lymphatic metastasis ( Figure 1B ). These results indicated that LINC00261 is involved in development of endometrial carcinoma.
3.2 | LINC00261 suppresses endometrial carcinoma cell proliferation, migration, and invasion 
| LINC00261 is a molecular sponge for miR-182, miR-183, miR-153, miR-27a, and miR-96
lncRNAs can act as molecular sponge for miRNAs. We used online tools (http://www.mircode.org and https://bibiserv.cebitec.
uni-bielefeld.de) to predict the potential LINC00261-interacted miRNAs. LINC00261 was predicted to interact with multiple miRNAs which had been reported to be upregulated in endometrial carcinoma, including miR-182, miR-183, miR-153, miR-27a, and miR-96 ( Figure 3A) . 20, 21 To prove the interaction between LINC00261
and these miRNAs, we first tested the inhibition effects of these miRNAs on the activity of Rellina fused with LINC00261 3′-UTR. As shown in Figure 3B , C, the activity of Rellina was inhibited by all these 5 miRNAs, but not by control miRNA, miR-191. Then, synthetic premiRNA of these 5 miRNAs and miR-191 were transfected into endometrial carcinoma cells, and all these 5 miRNAs, but not miRNAs, the MS-RIP assay was executed ( Figure 3H ). As shown in Figure 3I , J, LINC00261 efficiently pulled down these 5 miRNAs, but not miR-191. These data demonstrated that LINC00261 is a molecular sponge for miR-182, miR-183, miR-153, miR-27a, and miR-96.
| LINC00261 relieves the inhibitory effect of miRNAs on FOXO1 expression
These 5 miRNAs were reported to regulate expression of FOXO1, 8, 22 which plays important roles in the development of endometrial carcinoma. 7 So next, we investigated the effects of these 5 miRNAs on 
| LINC00261 suppresses endometrial carcinoma cell proliferation, migration, and invasion mediated by FOXO1
To test the function of FOXO1 in LINC00261 inhibition of endometrial carcinoma cell aggressiveness, FOXO1 was knocked down by stable expression of FOXO1 siRNA. As shown in Figure 5A -C, FOXO1
knockdown compromised the suppression effect of LINC00261 on cell proliferation and viability. Similar, LINC00261-suppressed migration ( Figure 5D ) and invasion ( Figure 5E ) both in Ishikawa and RL95-2 cells were eliminated by FOXO1 knockdown. These results suggested that LINC00261 suppresses endometrial carcinoma cell proliferation, migration, and invasion mediated by FOXO1.
FIGURE 2 LINC00261 suppresses cell proliferation, migration, and invasion in endometrial carcinoma cells. Ishikawa and RL95-2 cells were transfected with vector pcDNA or pCDNA expressing LINC00261, and then subject to G418 selection to establish cell lines stably expressing LINC00261. The levels of LINC00261 in the stable cells were determined by qRT-PCR. GAPDH acted as internal control A. The cell proliferation was measured by cell counting in Ishikawa B, and RL95-2 C, cells. D, Ishikawa and RL95-2 cells subjected to MTT assay to determine the cell viability after plated for 72 hours. The effects of LINC00261 on cell migration were evaluated by the transwell migration assay in Ishikawa E, and RL95-2 G, cells. The effects of LINC00261 on cell invasion were evaluated by the transwell invasion assay in Ishikawa F, and RL95-2 H, cells. Data are presented as mean ± SD. *P < .05, **P < .01
| DISCUSSION
In this study, we found that lncRNA LINC00261 was downregulated in endometrial carcinoma and associated with metastasis of this cancer. Now, we first time reported that LINC00261 was also downregulated in endometrial carcinoma, and the LINC00261 levels were further decreased in endometrial carcinoma with lymphatic metastasis.
Although our data showed similar LINC00261 functions on cancer cell aggressiveness as reported previously, 15, [17] [18] [19] 23 the molecular mechanisms are totally different. In colon cancer, LINC00261 downregulates Wnt signalling activity through restraining β-catenin from cytoplasm into nuclei and promoting β-catenin degradation. 23 In gastric cancer, LINC00261 interacts and destabilizes Slug protein, which is involved in epithelial-mesenchymal transitions and has antiapoptotic activity.
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FIGURE 3 LINC00261 is a molecular sponge for miR-182, miR-183, miR-153, miR-27a, and miR-96. The LINC00261-interacted miRNAs were predicted by online tools, and the binding sites of the predicted miRNAs on LINC00261 are schematically showed A. Rellina gene fused with LINC00261 3′-UTR, and the effects of miRNAs on the activity of Rellina-LINC00261 were measured by the dual-luciferase reporter assay in Ishikawa B, and RL95-2 C, cells. Firefly lucifease acted as internal control. LINC00261 expression was determined by qRT-PCR in Ishikawa D, and RL95-2 E, cells transfected with synthetic miRNA precursors. GAPDH was internal control. miRNA levels were determined by qRT-PCR and normalized to the level of U6 in Ishikawa F, and RL95-2 G, cells stably expressing LINC00261.H-J, The RIP assay was performed to pull down LINC00261 along with LINC00261-interacted miRNAs, and the amounts of miRNAs were determined by qRT-PCR. Data are presented as mean ± SD. *P < .05, **P < .01
In hepatocellular cancer, LINC00261 downregulates expression of induction is accompanied by G1 cell cycle arrest and cell death. 22 This study showed that 5 among these 8 miRNAs, including miR-182, miR-183, miR-153, miR-27a, and miR-96, were directly bound to and downregulated by LINC00261. These results indicated that high expression of these miRNAs in endometrial carcinoma is caused by low expression of LINC00261. This indication is supported by the data FIGURE 4 LINC00261 relieves the inhibitory effect of miRNA on FOXO1 expression. A-E, The potential miRNA binding sites at the 3′-UTR of FOXO1 were predicted by online tools and mutated to the sequences underlined. WT and mutated FOXO1 3′-UTR were fused with Rellina and cotransfected with synthetic miRNA precursors into Ishikawa F, and RL95-2 G, cells to perform dual-luciferase reporter assays. Western blot was used to analyse FOXO1 protein levels in Ishikawa H, and RL95-2 I, cells transfected with or without synthetic miRNA precursors. β-Actin serves as internal control. J, Western blot was performed to analyse FOXO1 protein levels in endometrial carcinoma cells stably expressing LINC00261. β-Actin serves as internal control. Data are presented as mean ± SD. *P < .05 that LINC00261 overexpression decreased these miRNA levels, and consequently increased FOXO1 protein levels and inhibited endometrial carcinoma cell aggressiveness. Thus, LNC00261 is suggested to play critical roles in the development of endometrial carcinoma, and to be an ideal potential target for therapy of endometrial carcinoma.
Although many papers described that LINC00261 expression is downregulated in many cancers, none of paper investigated the mechanisms underlying regulation of LINC00261 expression in cancers. This will be an interesting and important direction as the importance of LINC00261 in cancer development.
In conclusion, we first reported LINC00261 downregulation in endometrial carcinoma, and LINC00261 functions to prevent endometrial carcinoma aggressiveness. Mechanically, LINC00261 decreases FOXO1-targeted miRNAs to promote expression of FOXO1 which alleviates endometrial carcinoma cell proliferation, migration, and invasion.
| CONCLUSION
LINC00261 is downregulated in endometrial carcinoma and associated with metastasis of this cancer. LINC00261 elevates FOXO1 protein levels through reducing FOXO1-targeted miRNAs to suppress endometrial carcinoma cell proliferation, migration, and invasion.
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FIGURE 5 LINC00261 suppresses endometrial carcinoma cell proliferation, migration, and invasion mediated by FOXO1. FOXO1 was stably knocked down by FOXO siRNA in Ishikawa and RL95-2 cells stably overexpressing LINC00261, and then subject to proliferation analysis by cell counting A-B, cell viability analysis by MTT assay C, transwell migration assay D, and transwell invasion assay E. Data are presented as mean ± SD. *P < .05, **P < .01
